| 产品描述: | Etavopivat is a potent, selective, and orally active erythrocyte pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects that can be used in studies of sickle cell disease and other haemoglobinopathies[1][2]. |
| 体外研究: |
Etavopivat (500-1000 mg/kg,口服,每日一次,2 周) 可改善 SCA 小鼠的红细胞存活率和血红蛋白水平[1]。 Etavopivat (3-22 mg/kg,口服,每日一次,5 天) 在 8 mg/kg 和 22 mg/kg 剂量下导致食蟹猴体内 2,3-DPG 和 ATP 增加[2]。 |
| 参考文献: |
1. Shrestha A, et al. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Blood Adv. 2021 May 11;5(9):2385-2390. 2. Schroeder P, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.186 ml |
10.929 ml |
21.858 ml |
| 5 mM |
0.437 ml |
2.186 ml |
4.372 ml |
| 10 mM |
0.219 ml |
1.093 ml |
2.186 ml |
| 50 mM |
0.044 ml |
0.219 ml |
0.437 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |